Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BETAXON · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Brinzolamide suspension, 1% | EXPERIMENTAL | Dosed twice daily for 12 weeks |
| Levobetaxolol suspension, 0.5% | EXPERIMENTAL | Dosed twice daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| BETAXON (levobetaxolol HCl) | DRUG | levobetaxolol suspension, 0.5% |
| AZOPT (brinzolamide) | DRUG | brinzolamide suspension, 1% |
INCLUSION: * Children 5 years old and younger * require treatment for glaucoma or ocular hypertension * vision is 20/80 or better * cup-to-disc ratio of 0.8 or less EXCLUSION: * do not have abnormal fixation * IOP greater than 36 mm Hg * significant retinal disease * penetrating keratoplasty * se...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
BETAXON is an investigational small molecule being studied for the treatment of glaucoma and ocular hypertension. It is administered as an ophthalmic solution at a 0.5% concentration. The drug is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
BETAXON is a small molecule developed for ophthalmic use. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being evaluated for its safety and efficacy in reducing intraocular pressure in patients with glaucoma or ocular hypertension.
BETAXON is being developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker symbol ALC. Alcon is conducting clinical trials to evaluate the drug's safety and efficacy in pediatric patients with glaucoma or ocular hypertension.
BETAXON is in Phase 3 clinical development. It is an investigational drug and has not received FDA approval. The Phase 3 trial has been completed, with results expected to inform further regulatory and development decisions.
BETAXON has one completed Phase 3 clinical trial registered under NCT00061516. This randomized, double-blind, controlled study evaluated the safety and efficacy of BETAXON 0.5% compared to AZOPT 1.0% in 78 pediatric patients with glaucoma or ocular hypertension.
BETAXON is not the same as AZOPT. In the clinical trial NCT00061516, BETAXON 0.5% was studied as an active treatment and compared against AZOPT 1.0%, which served as the control. Both are ophthalmic solutions, but they are distinct drug products.